Alkermes (ALKS), Amylin (AMLN) Halted, Could Be Related to Bydureon Decision by FDA
Tweet
Share
E-mailGet Alerts ALKS Hot Sheet
Join SI Premium – FREE
Alkermes plc (Nasdaq: ALKS) and Amylin Pharmaceuticals (Nasdaq: AMLN) have been halted. The reasoning might be an FDA decision on Type 2 diabetes drug Bydureon. Tomorrow is the PDUFA for Bydureon.
The drug was confirmed on January 12th by the U.K.'s health-care cost-effectiveness body.
Eli Lilly (NYSE: LLY) is also part of the development of Bydureon.
The drug was confirmed on January 12th by the U.K.'s health-care cost-effectiveness body.
Eli Lilly (NYSE: LLY) is also part of the development of Bydureon.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Amplitude Therapeutics signs taRNA vaccine deal with Eli Lilly
- UGI Corp. (UGI) halted on volatility, up 6%
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Trading HaltsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
